# ChatGPT Response

{"answer": "", "cits": [{"pmid": "https://pubmed.ncbi.nlm.nih.gov/35965335/", "cit": "[1] Chen SY et al. (2022). \"ADCY5-related dyskinesia: a case report.\" Neurological research and practice, 4(1)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/36867608/", "cit": "[2] Tanzler D et al. (2023). \"Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients.\" PloS one, 18(3)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/23222958/", "cit": "[3] Fuchs T et al. (2013). \"Mutations in GNAL cause primary torsion dystonia.\" Nature genetics, 45(1)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/37476318/", "cit": "[4] Menon PJ et al. (2023). \"Scoping Review on ADCY5-Related Movement Disorders.\" Movement disorders clinical practice, 10(7)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/12223546/", "cit": "[5] Lee KW et al. (2002). \"Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase.\" The Journal of neuroscience : the official journal of the Society for Neuroscience, 22(18)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/35479074/", "cit": "[6] Pacini ESA et al. (2022). \"Extracellular cAMP-Adenosine Pathway Signaling: A Potential Therapeutic Target in Chronic Inflammatory Airway Diseases.\" Frontiers in immunology, 13()"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/29686613/", "cit": "[7] Ferre S et al. (2018). \"Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A(2A)-Dopamine D(2) Receptor Heterotetramers and Adenylyl Cyclase.\" Frontiers in pharmacology, 9()"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/31559390/", "cit": "[8] Ferre S et al. (2019). \"Functional and Neuroprotective Role of Striatal Adenosine A(2A) Receptor Heterotetramers.\" Journal of caffeine and adenosine research, 9(3)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/36634866/", "cit": "[9] Chen JF et al. (2023). \"Striatopallidal adenosine A(2A) receptor modulation of goal-directed behavior: Homeostatic control with cognitive flexibility.\" Neuropharmacology, 226()"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/19549762/", "cit": "[10] Fan P et al. (2009). \"Up-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neurons.\" Molecular pharmacology, 76(3)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/20096294/", "cit": "[11] Lovinger DM et al. (2010). \"Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum.\" Neuropharmacology, 58(7)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/22284188/", "cit": "[12] Lerner TN et al. (2012). \"RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits.\" Neuron, 73(2)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/30392131/", "cit": "[13] Haynes NS et al. (2019). \"Effects of adenosine A(2A) receptor antagonists on cocaine-induced locomotion and cocaine seeking.\" Psychopharmacology, 236(2)"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/38222898/", "cit": "[14] Yeow D et al. (2024). \"Genetic Testing of Movements Disorders: A Review of Clinical Utility.\" Tremor and other hyperkinetic movements (New York, N.Y.), 14()"}, {"pmid": "https://pubmed.ncbi.nlm.nih.gov/39000068/", "cit": "[15] Barik S et al. (2024). \"The Brain-Heart Network of Syncope.\" International journal of molecular sciences, 25(13)"}], "rcv_cit_count": 0, "rcv_cits": [], "status_answer_code": 0, "status_info_code": false, "cit_count": 42, "conversation_uuid": "78c29480-88a5-4e7c-8a02-cf5de5ee0bac", "triggering_question_lambda": false, "answer_uuid": ""}
The genomic variant c.1135-15351C>T rs1470044177 is located in the ADCY5 gene, which encodes the adenylyl cyclase type 5 enzyme. This enzyme is a member of the adenylyl cyclases family, responsible for converting adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), a critical secondary messenger involved in a variety of cellular processes. ADCY5 is predominantly expressed in the brain and heart, with high expression levels in the striatum and nucleus accumbens[1].The variant c.1135-15351C>T rs1470044177 itself is an intronic variant and does not directly alter the amino acid sequence of the ADCY5 protein. However, intronic variants can still have significant effects on gene function, such as altering the regulation of gene expression or affecting splicing mechanisms. The specific consequences of this variant on the ADCY5 gene's function are not detailed in the provided literature, and thus, the impact of this particular intronic variant remains to be fully elucidated.The function of the ADCY5 gene is critical in the brain, where cAMP signaling plays a pivotal role in neurotransmission and neuronal plasticity. In the striatum, ADCY5 is involved in the modulation of dopamine and adenosine receptor signaling pathways, which are essential for motor control and other neurological functions[5]. Dysregulation of ADCY5 activity has been implicated in movement disorders, as gain-of-function mutations in the gene can lead to ADCY5-related dyskinesia, a condition characterized by involuntary movements such as dystonia, chorea, myoclonus, and tremor[1][4].Therapeutic interventions for conditions associated with ADCY5 mutations have been explored, with some patients experiencing partial improvement in dyskinesia symptoms with caffeine treatment, which antagonizes A2A receptors and may counteract abnormal ADCY5 activity[1]. Other studies have investigated the effects of purine derivatives like theophylline and istradefylline on cAMP levels, which are relevant to the treatment of ADCY5-related dyskinesia due to their ability to reduce cAMP concentrations[2].In summary, the ADCY5 gene plays a crucial role in cAMP signaling within the brain, particularly in the striatum, and is implicated in the pathogenesis of movement disorders. The specific intronic variant c.1135-15351C>T rs1470044177's impact on gene function is not clearly defined in the provided literature, but intronic variants can influence gene expression and splicing, potentially leading to disease. Further research is needed to understand the full implications of this and other intronic variants in ADCY5.